Mallinckrodt plc was incorporated in Ireland on January 9, 2013 for the purpose of holding the Pharmaceuticals business of Covidien plc ("Covidien"). On June 28, 2013, Covidien shareholders of record received one ordinary
share of Mallinckrodt for every eight ordinary shares of Covidien held as of the record date, June 19, 2013,
and the Pharmaceuticals business of Covidien was transferred to Mallinckrodt plc, thereby completing the legal
separation from Covidien ("the Separation"). On July 1, 2013, Mallinckrodt plc began regular trading on the
New York Stock Exchange under the ticker symbol "MNK."
This is spinoff from Covidien I received recently. Any information on MNK is encouraged. |
